Education
About Us
Working with TipRanks
Follow Us
Noile-Immune Biotech Inc. (JP:4893)
:4893
Total Valuation
Noile-Immune Biotech Inc. has a market cap or net worth of ¥6.97B. The enterprise value is ¥2.84B.
Market Cap¥6.97B
Enterprise Value¥2.84B
Share Statistics
Noile-Immune Biotech Inc. has 43,276,764 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding43,276,764
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Noile-Immune Biotech Inc.’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -20.25%.
Return on Equity (ROE)-0.20
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-20.25%
Return on Capital Employed (ROCE)-0.20
Revenue Per Employee200.00K
Profits Per Employee-31.74M
Employee Count25
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Noile-Immune Biotech Inc. is ―. Noile-Immune Biotech Inc.’s PEG ratio is 0.41.
PE Ratio―
PS Ratio1151.82
PB Ratio1.46
Price to Fair Value1.46
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.41
Income Statement
In the last 12 months, Noile-Immune Biotech Inc. had revenue of 5.00M and earned -793.54M in profits. Earnings per share was -18.33.
Revenue5.00M
Gross Profit5.00M
Operating Income-797.25M
Pretax Income-791.12M
Net Income-793.54M
EBITDA-797.25M
Earnings Per Share (EPS)-18.33
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Noile-Immune Biotech Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.48
52-Week Price Change-11.36%
50-Day Moving Average145.66
200-Day Moving Average163.34
Relative Strength Index (RSI)55.17
Average Volume (3m)85.17K
Important Dates
Noile-Immune Biotech Inc. upcoming earnings date is May 19, 2026, TBA (Confirmed).
Last Earnings DateFeb 13, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Noile-Immune Biotech Inc. as a current ratio of 53.54, with Debt / Equity ratio of 0.00%
Current Ratio53.54
Quick Ratio53.51
Debt to Market Cap0.00
Net Debt to EBITDA4.91
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Noile-Immune Biotech Inc. has paid 2.42M in taxes.
Income Tax2.42M
Effective Tax Rate>-0.01
Enterprise Valuation
Noile-Immune Biotech Inc. EV to EBITDA ratio is -2.31, with an EV/FCF ratio of 0.00.
EV to Sales368.16
EV to EBITDA-2.31
EV to Free Cash Flow0.00
EV to Operating Cash Flow-2.45
Balance Sheet
Noile-Immune Biotech Inc. has ¥4.31B in cash and marketable securities with ¥0.00 in debt, giving a net cash position of ¥4.31B billion.
Cash & Marketable Securities¥4.31B
Total Debt¥0.00
Net Cash¥4.31B
Net Cash Per Share¥99.67
Tangible Book Value Per Share¥90.80
Margins
Gross margin is 85.28%, with operating margin of -15945.08%, and net profit margin of -15870.72%.
Gross Margin85.28%
Operating Margin-15945.08%
Pretax Margin-15822.32%
Net Profit Margin-15870.72%
EBITDA Margin-15945.08%
EBIT Margin-15945.08%
Analyst Forecast
The average price target for Noile-Immune Biotech Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-12.01%
EPS Growth Forecast26.66%